Skip to content

Cancer Health Center

Font Size

Childhood Central Nervous System Embryonal Tumors Treatment (PDQ®): Treatment - Health Professional Information [NCI] - Treatment Option Overview for CNS Embryonal Tumors

Table 3. Standard Treatment Options for Childhood Central Nervous System (CNS) Embryonal Tumors

Stage and/or Histopathologic ClassificationStandard Treatment Options
Newly diagnosed childhood medulloblastoma:
Children older than 3 years with average-risk medulloblastomaSurgery
Adjuvant therapy(radiation therapy and chemotherapy)
Children older than 3 years with high-risk medulloblastomaSurgery
Adjuvant therapy(radiation therapy and chemotherapy)
Children aged 3 years and youngerSurgery
Adjuvant chemotherapy
Newly diagnosed CNS primitive neuroectodermal tumor:
Children older than 3 yearsSurgery
Adjuvant therapy(radiation therapy and chemotherapy)
Children aged 3 years and youngerSimilar to children aged 3 years and younger with medulloblastoma (surgery and adjuvant chemotherapy)
Newly diagnosed medulloepithelioma and ependymoblastomaSame as for children with high-risk medulloblastoma (surgery and adjuvant therapy) and children aged 3 years and younger with other embryonal tumors
Newly diagnosed pineoblastoma:
Children older than 3 yearsSurgery
Adjuvant therapy(radiation therapy and chemotherapy)
Children aged 3 years and youngerBiopsy(for diagnosis)
Chemotherapy
High-dose, marrow-ablative chemotherapy with autologous bone marrow rescue or peripheral stem cell rescue
Recurrent childhood CNS embryonal tumors (treatment options not considered standard)Surgery
Radiation therapy
Chemotherapy
High-dose chemotherapy with stem cell rescue

References:

  1. Zeltzer PM, Boyett JM, Finlay JL, et al.: Metastasis stage, adjuvant treatment, and residual tumor are prognostic factors for medulloblastoma in children: conclusions from the Children's Cancer Group 921 randomized phase III study. J Clin Oncol 17 (3): 832-45, 1999.
  2. Giangaspero F, Wellek S, Masuoka J, et al.: Stratification of medulloblastoma on the basis of histopathological grading. Acta Neuropathol 112 (1): 5-12, 2006.
  3. Eberhart CG, Kratz J, Wang Y, et al.: Histopathological and molecular prognostic markers in medulloblastoma: c-myc, N-myc, TrkC, and anaplasia. J Neuropathol Exp Neurol 63 (5): 441-9, 2004.
  4. Taylor MD, Northcott PA, Korshunov A, et al.: Molecular subgroups of medulloblastoma: the current consensus. Acta Neuropathol 123 (4): 465-72, 2012.

This information is produced and provided by the National Cancer Institute (NCI). The information in this topic may have changed since it was written. For the most current information, contact the National Cancer Institute via the Internet web site at http:// cancer .gov or call 1-800-4-CANCER.

WebMD Public Information from the National Cancer Institute

Last Updated: 8/, 015
This information is not intended to replace the advice of a doctor. Healthwise disclaims any liability for the decisions you make based on this information.
1|2
1|2
Next Article:

Today on WebMD

Colorectal cancer cells
New! I AM Not Cancer Facebook Group
Lung cancer xray
See it in pictures, plus read the facts.
 
sauteed cherry tomatoes
Fight cancer one plate at a time.
Ovarian cancer illustration
Real Cancer Perspectives
 
Jennifer Goodman Linn self-portrait
Blog
what is your cancer risk
HEALTH CHECK
 
colorectal cancer treatment advances
Video
breast cancer overview slideshow
SLIDESHOW
 
prostate cancer overview
SLIDESHOW
lung cancer overview slideshow
SLIDESHOW
 
ovarian cancer overview slideshow
SLIDESHOW
Actor Michael Douglas
Article